keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ixazomib citrate (MLN9708) 是 Ixazomib 的前药,是20S 蛋白酶体胰凝乳蛋白酶样蛋白水解β5位点的可逆抑制剂,IC50为3.4 nM 和Ki 为0.93 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 198 | 现货 | ||
5 mg | ¥ 413 | 现货 | ||
10 mg | ¥ 578 | 现货 | ||
25 mg | ¥ 919 | 现货 | ||
50 mg | ¥ 1,230 | 现货 | ||
100 mg | ¥ 1,960 | 现货 | ||
500 mg | ¥ 4,830 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 472 | 现货 |
产品描述 | Ixazomib citrate (MLN9708) is a prodrug of Ixazomib (MMLN-2238). MLN9708 is an orally bioavailable second generation proteasome inhibitor (IC50 of 3.4 nM ) with potential antineoplastic activity. |
靶点活性 | 20S proteasome β5:3.4 nM , 20S proteasome β2:3500 nM, 20S proteasome β1:31 nM |
体外活性 | Treatment of MM cells with MLN2238 predominantly inhibits chymotrypsin-like activity of the proteasome and induces accumulation of ubiquitinated proteins. MLN2238 inhibits growth and induces apoptosis in MM cells resistant to conventional and bortezomib therapies without affecting the viability of normal cells[1]. |
体内活性 | In animal tumor model studies, MLN2238 is well tolerated and inhibits tumor growth with significantly reduced tumor recurrence. A head-to-head analysis of MLN2238 versus bortezomib showed a significantly longer survival time in mice treated with MLN2238 than mice receiving bortezomib[1]. |
别名 | 枸橼酸艾沙佐米, MLN9708 |
分子量 | 517.12 |
分子式 | C20H23BCl2N2O9 |
CAS No. | 1239908-20-3 |
keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (193.38 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.9338 mL | 9.6689 mL | 19.3379 mL | 48.3447 mL |
5 mM | 0.3868 mL | 1.9338 mL | 3.8676 mL | 9.6689 mL | |
10 mM | 0.1934 mL | 0.9669 mL | 1.9338 mL | 4.8345 mL | |
20 mM | 0.0967 mL | 0.4834 mL | 0.9669 mL | 2.4172 mL | |
50 mM | 0.0387 mL | 0.1934 mL | 0.3868 mL | 0.9669 mL | |
100 mM | 0.0193 mL | 0.0967 mL | 0.1934 mL | 0.4834 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Ixazomib citrate 1239908-20-3 Autophagy Proteases/Proteasome Ubiquitination Proteasome Ixazomib Inhibitor MLN 9708 枸橼酸艾沙佐米 Ixazomib Citrate MLN-9708 inhibit MLN9708 inhibitor